COMMUNIQUÉ RÉGLEMENTÉ
News
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to test efficacy and safety for muscle function in obese patients. Study to start mid-2024 with results expected in 2025 -
-
-
-
COMMUNIQUÉ DE PRESSE
Biophytis is deploying its partnership strategy in obesity
Biophytis announces the implementation of a dedicated partnership strategy in obesity, aiming to collaborate with global pharmaceutical companies for drug development and commercialization. CEO Stanislas Veillet emphasizes the importance of addressing the obesity medical challenge through partnerships -
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Biophytis déploie sa stratégie de partenariat dans le domaine de l’obésité
Biophytis déploie une stratégie de partenariat dans le domaine de l’obésité pour le développement de traitements révolutionnaires. La société recherche des partenaires pour licencier son candidat-médicament BIO101 -
COMMUNIQUÉ RÉGLEMENTÉ
Biophytis is deploying its partnership strategy in obesity
Biophytis announces partnership strategy for obesity, aiming to license out drug candidate BI0101 to global pharma companies for development, launch, and commercialization. CEO stresses importance of partnering for medical innovation
